Cas no 1225-01-0 (Estran-17-one,3-hydroxy-, (3a,5a)-)
Estran-17-one,3-hydroxy-, (3a,5a)- Chemical and Physical Properties
Names and Identifiers
-
- Estran-17-one,3-hydroxy-, (3a,5a)-
- (8R,9R,10S,13S,14S)-3-hydroxy-13-methyl-2,3,4,5,6,7,8,9,10,11,12,14,15,16-tetradecahydro-1H-cyclopenta[a]phenanthren-17-one
- 19-Norandrosterone
- 3-hydroxyestran-17-one
- estran-17-one, 3-hydroxy-
- LMST02010042
- DTXSID10893662
- J109.668K
- Estran-17-one, 3-hydroxy-, (3.alpha.,5.alpha.)-
- (3a,5a)-3-hydroxy-Estran-17-one
- 3-Hydroxyestran-17-one #
- 5alpha-19-norandrosterone
- 3a-hydroxy-5a-Estran-17-one
- UOUIARGWRPHDBX-CQZDKXCPSA-N
- 3alpha-hydroxy-5alpha-estran-17-one
- (3aS,3bR,5aS,7R,9aS,9bR,11aS)-7-hydroxy-11a-methyl-hexadecahydro-1H-cyclopenta[a]phenanthren-1-one
- SCHEMBL1220486
- (3R,5S,8R,9R,10S,13S,14S)-3-hydroxy-13-methyl-2,3,4,5,6,7,8,9,10,11,12,14,15,16-tetradecahydro-1H-cyclopenta[a]phenanthren-17-one
- 5alpha-Estran-3alpha-ol-17-one
- 5alpha-Estran-17-one, 3alpha-hydroxy-
- 19-Noreoiandrosterone
- 3alpha-Hydroxy-5alpha-estran-17-one; 19-Norandrosterone; 5alpha-Estran-3alpha-ol-17-one
- 5W4XKU708V
- 1225-01-0
- 5.alpha.-Estran-17-one, 3.alpha.-hydroxy-
- 5a-Estran-3a-ol-17-one
- 5.alpha.-Estran-3.alpha.-ol-17-one
- Q10859482
- UNII-5W4XKU708V
- CHEBI:36412
- 19-Norandrosterone (1.0 mg/ml in Methanol)
- PD076329
- Estran-17-one, 3-hydroxy-, (3alpha,5alpha)-
- h_14_19_norandrosterone
- CHEMBL3638321
-
- Inchi： 1S/C18H28O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h11-16,19H,2-10H2,1H3/t11-,12+,13-,14+,15+,16-,18-/m0/s1
- InChI Key： UOUIARGWRPHDBX-CQZDKXCPSA-N
- SMILES： O=C1CC[C@@H]2[C@]1(C)CC[C@@H]1[C@H]3CC[C@H](C[C@@H]3CC[C@H]12)O
Computed Properties
- Exact Mass: 276.208930132g/mol
- Monoisotopic Mass: 276.208930132g/mol
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 1
- Hydrogen Bond Acceptor Count: 2
- Heavy Atom Count: 20
- Rotatable Bond Count: 0
- Complexity: 418
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 7
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- XLogP3: 3.3
- Topological Polar Surface Area: 37.3?2
Experimental Properties
- LogP: 3.887
Estran-17-one,3-hydroxy-, (3a,5a)- Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| XI GE MA AO DE LI QI （ SHANG HAI ） MAO YI Co., Ltd. | NMID555B-1MG |
Estran-17-one,3-hydroxy-, (3a,5a)- |
1225-01-0 | NMI Australia | ￥1956.12 | 2022-02-23 | ||
| XI GE MA AO DE LI QI （ SHANG HAI ） MAO YI Co., Ltd. | NMID555B-1MG |
1225-01-0 | 1MG |
￥2262.8 | 2023-01-17 |
Estran-17-one,3-hydroxy-, (3a,5a)- Related Literature
-
M. Ventura,A. Sanchez-Niubo,F. Ruiz,N. Agell,R. Ventura,C. Angulo,A. Domingo-Salvany,J. Segura,R. de la Torre Analyst 2008 133 105
-
Liangyu Xue,Yunjiao Zhao,Huiting Wang,Zongqi Li,Tao Wu,Rui Liu,Wenjie Sui,Min Zhang Food Funct. 2023 14 4632
-
Marco Beccaria,Deirdre Cabooter Analyst 2020 145 1129
-
James R. Hanson Nat. Prod. Rep. 2010 27 887
-
Moritz Hebestreit,Ulrich Flenker,Gregor Fu?h?ller,Hans Geyer,Ute Güntner,Ute Mareck,Thomas Piper,Mario Thevis,Christiane Ayotte,Wilhelm Sch?nzer Analyst 2006 131 1021
Additional information on Estran-17-one,3-hydroxy-, (3a,5a)-
Recent Advances in the Study of Estran-17-one,3-hydroxy-, (3a,5a)- (CAS: 1225-01-0)
Estran-17-one,3-hydroxy-, (3a,5a)- (CAS: 1225-01-0) is a steroidal compound that has garnered significant attention in the field of chemical biology and pharmaceutical research due to its potential therapeutic applications. Recent studies have focused on elucidating its molecular mechanisms, synthetic pathways, and biological activities, particularly in the context of hormone-related disorders and cancer therapy. This research brief aims to summarize the latest findings and advancements related to this compound, providing a comprehensive overview for professionals in the field.
One of the key areas of investigation has been the synthesis and structural modification of Estran-17-one,3-hydroxy-, (3a,5a)-. Researchers have developed novel synthetic routes to improve yield and purity, leveraging advanced techniques such as asymmetric catalysis and green chemistry principles. These advancements not only enhance the scalability of production but also open new avenues for the development of derivatives with improved pharmacological properties. For instance, a recent study published in the Journal of Medicinal Chemistry demonstrated the successful synthesis of a series of analogs with enhanced binding affinity to steroid hormone receptors.
In addition to synthetic improvements, the biological activities of Estran-17-one,3-hydroxy-, (3a,5a)- have been extensively studied. Preclinical models have shown that this compound exhibits potent anti-inflammatory and anti-proliferative effects, making it a promising candidate for the treatment of hormone-dependent cancers such as breast and prostate cancer. Mechanistic studies have revealed that it modulates key signaling pathways, including the estrogen receptor (ER) and androgen receptor (AR) pathways, thereby inhibiting tumor growth and metastasis. These findings were corroborated by in vitro and in vivo experiments, as reported in a recent issue of Cancer Research.
Another significant development is the exploration of Estran-17-one,3-hydroxy-, (3a,5a)- in neurodegenerative diseases. Preliminary data suggest that this compound may have neuroprotective properties, potentially through its interaction with glucocorticoid receptors. A study published in Neuropharmacology highlighted its ability to reduce oxidative stress and inflammation in neuronal cells, offering a new therapeutic strategy for conditions like Alzheimer's disease. However, further research is needed to validate these findings and assess the compound's safety profile in clinical settings.
Despite these promising advancements, challenges remain in the clinical translation of Estran-17-one,3-hydroxy-, (3a,5a)-. Issues such as bioavailability, metabolic stability, and potential off-target effects need to be addressed through rigorous pharmacokinetic and toxicological studies. Collaborative efforts between academia and industry are essential to overcome these hurdles and accelerate the development of this compound into viable therapeutics. Recent partnerships, as reported in Pharmaceutical Technology, have focused on optimizing formulation strategies to enhance drug delivery and efficacy.
In conclusion, Estran-17-one,3-hydroxy-, (3a,5a)- (CAS: 1225-01-0) represents a versatile and promising scaffold in chemical biology and pharmaceutical research. The latest studies underscore its potential in treating hormone-related disorders, cancer, and neurodegenerative diseases, while also highlighting the need for further investigation to fully realize its therapeutic benefits. As research progresses, this compound is poised to make significant contributions to the field, offering new hope for patients and advancing our understanding of steroidal pharmacology.
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
